Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173004
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin-angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.
Matèries
Matèries (anglès)
Citació
Citació
GÓRRIZ, José luis, SOLER, María josé, NAVARRO GONZÁLEZ, Juan f., GARCÍA CARRO, Clara, PUCHADES, María jesús, MARCO, Luis d’, MARTÍNEZ CASTELAO, Alberto, FERNÁNDEZ FERNÁNDEZ, Beatriz, ORTIZ, Alberto, GÓRRIZ ZAMBRANO, Carmen, NAVARRO PÉREZ, Jorge, GORGOJO MARTÍNEZ, Juan josé. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. _Journal of Clinical Medicine_. 2020. Vol. 9, núm. 4. [consulta: 25 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/173004]